Clinical trial NCT06775054: Cognitive Flexibility in Depression and TMS Response
Official title: The Role of Cognitive Flexibility in Depression and Response to Transcranial Magnetic Stimulation (TMS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression - Major Depressive Disorder
Cognitive Flexibility
Treatment Response
Side Effects
Keywords: Depression
TMS
TRD
WCST
TMT
VF
Lead sponsor: Gulhane Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2025-01-14
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The Treatment-Resistant Depression (TRD) patient group will be evaluated before and after Transcranial Magnetic Stimulation (TMS) treatment. There will also be a control group consisting of healthy participants, who will undergo a single neuropsychological and clinical assessment. Cognitive flexibility will only be evaluated before the TMS procedure using neuropsychological assessment tools.
Primary purpose: SCREENING

Brief summary: The primary aim of this study is to determine the level of cognitive flexibility in patients with TRD before treatment and to explore whether there is a relationship with their response to TMS treatment. More specifically, the study aims to identify the role of cognitive flexibility as a neurocognitive marker that could predict whether patients planned to undergo TMS treatment will respond to the treatment. The main focus of this study is to ascertain whether the data obtained have practical implications, particularly regarding the identification of TRD patients who do not respond to TMS treatment in advance.

Detailed description: The primary aim of this prospective study is to determine the level of cognitive flexibility in patients with treatment-resistant depression (TRD) before treatment and to explore whether there is a relationship between cognitive flexibility and their response to TMS treatment. TRD represents a subset of major depressive disorder in which patients do not adequately respond to conventional antidepressant treatments. Emerging evidence suggests that TMS, a noninvasive brain stimulation technique, can effectively alleviate symptoms in TRD patients. However, the Stanford Accelerated Intelligent Neuromodulation Therapy study suggests that 20% of the TRD group may not respond to treatment and could represent an endophenotypic subgroup. In this context, patients with better cognitive flexibility may show a better response to TMS, and the addition of behavioral methods to enhance flexibility could be considered as an adjunct to TMS treatment.

The study will enroll 49 patients diagnosed with treatment-resistant depression (TRD) based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. Participants will undergo a TMS treatment regimen using the MagVenture™ X100™ device. The treatment protocol will consist of 20 sessions over four weeks, delivering 18,000 pulses in total (using theta burst stimulation). The stimulation will target the left dorsolateral prefrontal cortex, with parameters designed to achieve optimal therapeutic effects while minimizing side effects. Motor threshold measurements will be conducted prior to treatment initiation and adjusted weekly to maintain consistent treatment intensity.

A control group consisting of 65 healthy participants will undergo a single evaluation for neuropsychological and psychometric assessments, with no treatment or follow-up.

Before starting TMS treatment, all patients will undergo a neuropsychological test battery, including the Wisconsin Card Sorting Test (WCST), Trail Making Test (TMT, Verbal Fluency (VF) Tests to determine their cognitive flexibility levels. The Cognitive Flexibility and Control Scale (CFCS), a self-report measure, will be administered to patients who meet the eligibility criteria. Psychiatric assessments will include the Patient Health Questionnaire (PHQ-9) to evaluate changes in depressive symptoms, while the Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) scales will be administered before and after the 20 sessions of TMS treatment.

The primary objective is to assess improvements in symptom severity and the relationship with cognitive flexibility, as measured by the neurocognitive test battery. This will provide valuable insights for clinicians to better understand which patients are most likely to benefit from TMS treatment. The secondary objectives include identifying clinical and neurocognitive features in patients who do not respond to TMS treatment, assessing side effects, and examining whether concurrent medication, such as anti-obsessive medications, influences the efficacy of TMS therapy.This study will offer valuable data for clinicians and researchers, ultimately guiding safer and more effective use of TMS in psychiatric practice.

Eligibility criteria: Inclusion Criteria:

Diagnosed with Major Depressive Disorder according to DSM-5 TR.

* Diagnosed with Obsessive-Compulsive Disorder according to DSM-5 TR.
* Lack of response to treatment after being administered at least two different antidepressants and anti-obsessive agents at effective doses and durations.
* The clinical condition cannot be better explained by a metabolic or organic disorder.
* Routine electroencephalography (EEG) findings before TMS do not indicate electrical activity consistent with an epileptic focus.
* Routine blood tests before TMS show no conditions that could affect treatment levels, particularly thyroid issues, vitamin deficiencies, or inflammation parameters that might cause depression or cognitive impairment (consultation with relevant departments if necessary).
* No history of hearing loss identified during routine evaluations (if a history of hearing loss exists, consultation will be requested; if none, the process will proceed accordingly).

Exclusion Criteria:

* According to the pre-TMS risk assessment form, there is a contraindication for treatment,
* Epileptic focus is detected in the pre-TMS electroencephalography findings,
* Previous head trauma, loss of consciousness and intra-cerebral surgery,
* A metal particle caused by an aneurysm clip, connection tongs or explosive substances that will affect the electromagnetic field in the brain,
* A significant disorder in the thyroid hormone profile in routine blood checks before TMS,
* A significant increase in inflammation markers in routine checks before TMS,
* A vitamin deficiency that may cause cognitive impairment or forgetfulness in routine blood checks before TMS,
* A presence of electrolyte imbalance in routine blood checks before TMS,
* The patient has previously had a psychotic attack or bipolar mood attack,
* The patient has previously had a substance-induced psychosis or bipolar mood disorder,
* The patient has previously used substances known as alcohol, drugs or stimulants according to DSM-V TR and semi-structured clinical interview (SCID-5 TR) have abuse or addiction (except if they have not used in the last 12 months or have not abused alcohol),
* Those who want to terminate TMS treatment voluntarily, Note:If an unexpected clinical situation occurs during TMS treatment, the patient will be excluded from the study.

Primary outcomes:
measure: Assessing Cognitive Flexibility in TMS Treatment:WCST
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Exploring Changes in Task-Switching Ability: The Effect of TMS on TMT Performance
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Evaluating Changes in Verbal Fluency Pre- and Post-TMS Treatment
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Cognitive Flexibility as a Predictor of Transcranial Magnetic Stimulation Outcomes
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Assessing Depression Severity Before and After Transcranial Magnetic Stimulation Treatment
timeFrame: From enrollment to the end of the treatment at 4 weeks.
measure: Evaluating Response to TMS Treatment Using the Clinical Global Impression Scale (CGI)
timeFrame: From enrollment to the end of treatment at 4 weeks
Secondary outcomes:
measure: Tracking Depression Severity Changes
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Side Effect Assessment
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Drug Interaction Effects
timeFrame: From enrollment to the end of treatment at 4 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gulhane Training and Research Hospital
Study officials:
affiliation: Gulhane Trainin and Research Hospital
name: BEYAZIT GARİP, Medical Doctor
role: PRINCIPAL_INVESTIGATOR
References: